… drug action can be used to predict the likely benefit of new combinations (53). We also discuss
why independent action … germ-cell tumors; in these cases, drugs exhibit additivity (54). We …

… and this is why no single drug has been effective in “curing” cancer. … precision oncology.
Here we describe a few recent policy and research advances in the field of precision oncology. …

… A vital factor in advancing precision oncology strategies is the availability of therapeutic
options that are determined on the basis of a particular molecular test – without this, there is little …

… to drugs. This field, called pharmacogenomics, is a key area in the development of precision
oncology. … of patients), prediction of drug response and drug synergy for individual tumors (…

… Off-label use of cancer drugs in oncology has a long history, 81-83 particularly in patients
with rare cancer types for whom randomized clinical trials may not be feasible. Access to …

… of drug repurposing within precision oncology, with a focus on combinatorial approaches. …
” drug repurposing in precision oncology. We discuss off-label use of anticancer drugs, …

… If these challenges are addressed appropriately to inform drug discovery, disease diagnosis,
and treatment decisions, improved precision oncology will be made available for a wide …

… therapies (eg one-person trials) to fully realize the promise of precision medicine. We … for
precision oncology. Finally, we highlight several new directions for the precision oncology drug …

… drug polypharmacology is currently being exploited in precision oncology, using US Food
and Drug … as a means of establishing a link between drug binding and efficacy. Second, we …

… Under the regime of actionability that characterises precision oncology, the interpretation of
a given variant includes the potential effects of specific drugs on that variant. In other words, …